SCHEMBL30439960

CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](N)Cc1ccc(O)cc1)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CC(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](Cc1c[nH]cn1)C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)NCC(=O)NCC(=O)N[C@@H](CCCCNC(=O)CCCC[C@@H]1SC[C@@H]2NC(=O)N[C@@H]21)C(N)=O)[C@@H](C)O

nearest known ligand 0.57

Predicted protein targets (top 12)

	gene	UniProt	supporting neighbours	confidence
▸	C5AR1	P21730	2/20	0.57

▸	OPRD1	P41143	8/20	0.55

▸	GLP1R	P43220	3/20	0.54

▸	GCGR	P47871	3/20	0.54

▸	MC4R	P32245	1/20	0.52

▸	OPRM1	P35372	2/20	0.52

▸	OPRK1	P41145	2/20	0.52

▸	RAMP3	O60896	2/20	0.51

▸	CALCR	P30988	2/20	0.51

▸	RAMP1	O60894	1/20	0.51

▸	RAMP2	O60895	1/20	0.51

▸	CALCRL	Q16602	1/20	0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compound	similarity	top predicted	shared targets
SCHEMBL30439872	0.96	C5AR1 (0.60)	C5AR1OPRD1GLP1RGCGRMC4R
SCHEMBL30440071	0.91	C5AR1 (0.63)	C5AR1GLP1RGCGR
SCHEMBL30439719	0.91	C5AR1 (0.62)	C5AR1GLP1RGCGR
SCHEMBL30439604	0.90	C5AR1 (0.64)	C5AR1GLP1RGCGR
SCHEMBL30439693	0.90	C5AR1 (0.65)	C5AR1GLP1RGCGR
SCHEMBL30440019	0.89	C5AR1 (0.66)	C5AR1GLP1RGCGR
SCHEMBL30440022	0.89	C5AR1 (0.59)	C5AR1OPRD1GLP1RGCGRRAMP3
SCHEMBL30439961	0.89	C5AR1 (0.55)	C5AR1OPRD1GLP1RGCGRMC4R
SCHEMBL30440054	0.89	C5AR1 (0.64)	C5AR1GLP1RGCGR
SCHEMBL30440404	0.89	C5AR1 (0.60)	C5AR1GLP1RGCGR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

Patent	Title	Assignee	Published	Priority	Filing	Country	Status
US-20230173086-A1	PEPTIDE CONJUGATES AND THERAPEUTIC AGENTS HAVING IMPROVED PHARMACOLOGICAL AND PHARMACOKINETIC PROPERTIES	EAGLE RESOLUTE INVESTMENT LLC	2023-06-08	—	—	US	disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

Patent	Title	Text reads most about	Predicted target · text-rank
US-20230173086-A1	PEPTIDE CONJUGATES AND THERAPEUTIC AGENTS HAVING IMPROVED PHARMACOLOGICAL AND PHARMACOKINETIC PROPERTIES	VIP, DNPEP, CD74	C5AR1 140/4885OPRD1 3854/4885GLP1R 501/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.